The FDA's approval of the first CRISPR-Cas9–based gene therapy marked a major milestone in biomedicine, validating genome ...

Trem2-H157Y knock-in. CRISPR/Cas9 gene editing was used to introduce the H157Y mutation into the mouse Trem2 gene. This variant first gained attention when it was found to associate with an increased ...

AAV applications of all kinds are limited by the AAV particle’s payload capacity, which is 4.5–4.9 Kb. For example, in CRISPR research, the AAV particle has difficulty packaging CRISPR-Cas9 ...

A team from UC San Diego, John Hopkins and UC Berkeley Universities found a way to edit a single gene in a mosquito that ...

Learn more about CRISPR in this summary article. Avoiding CRISPR Off-Target Effects by Tweaking the Timing of Edits Double-strand DNA breaks not only open the door to unwanted, off-target editing, but ...

MyoGene will use this funding to advance development of MyoDys 45-55, an AAV-delivered CRISPR/Cas9 gene editing approach that would be applicable to up to 50 percent of all DMD patients.

AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice. eBioMedicine, 2023; 93: 104682 DOI: 10.1016/j.ebiom.2023.104682 ...

Executive Summary The CRISPR-Cas9 patent landscape remains complex and unsettled. The Federal Circuit’s latest decision in University of California v. Broad Institute 1 revived the high-stakes ...

For a decade, leading academic institutes and their associated companies fought a bruising fight over who held patent rights to CRISPR-Cas9. Editas Medicine will now cash in.

The gene editing technique CRISPR/Cas9 has allowed researchers to make precise and impactful changes to an organism's DNA to fix mutations that cause genetic disease.